PRL significantly enhances the number of cells secreting antibodies directed against myelin oligodendrocyte glycoprotein (MOG) in MS subjects and upregulates the expression of B cell activating factor (BAFF) and the anti-apoptotic molecule Bcl2, via a Jak2/STAT-dependent pathway [46]. Here, TNFSF13B is linked to myeloid sarcoma.